Received Feb 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Incomplete 2nd dose; Vaccine in contact with the patient skin; Vaccine in contact with the patient skin; the needle was not secure enough; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of incomplete dose administered in a 75-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in October 2024). On 07-FEB-2025, the patient received the 2nd dose of Shingrix. On 07-FEB-2025, an unknown time after receiving Shingrix, the patient experienced incomplete dose administered (Verbatim: Incomplete 2nd dose), exposure via skin contact (Verbatim: Vaccine in contact with the patient skin), inadvertent exposure to vaccine (Verbatim: Vaccine in contact with the patient skin) and wrong technique in product usage process (Verbatim: the needle was not secure enough). The outcome of the incomplete dose administered, exposure via skin contact, inadvertent exposure to vaccine and wrong technique in product usage process were not applicable. Additional Information: GSK Receipt Date: 17-FEB-2025 On 17th February 2025 a registered pharmacist called and reported the following that they had an incident, where they were administering the 2nd dose for Shingrix vaccine, and the needle wasn't secure enough which led to wrong technique in product usage process, so when they injected the vaccine some squirted out for in-between the needle and the syringe which led to incomplete dose administration. Do they need to readminister the 2nd dose? The vaccine administration facility was the same as primary reporter. The 1st dose was administered in October 2024, but never specified the date. Healthcare professional mentioned that due to the situation the vaccine got in contact with the patient's skin which led to exposure via skin contact and inadvertent exposure to vaccine.